Effects of sevelamer and calcium on coronary artery calcification in patients new to dialysis: Time for better controlled clinical trials [3]

Kidney International

Volumn 69, Issue 6, 2006, Pages 1093-

  Qunibi, W Y ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHATE BINDING AGENT; SEVELAMER; STATIN;

ARTERY CALCIFICATION; BONE DISEASE; CARDIAC PATIENT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DRUG EFFECT; HUMAN; LETTER; PRIORITY JOURNAL;

CALCINOSIS; CALCIUM; CHOLESTEROL; CHOLESTEROL, LDL; CONTROLLED CLINICAL TRIALS; CORONARY ARTERIOSCLEROSIS; DISEASE PROGRESSION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PHOSPHATE-BINDING PROTEINS; POLYAMINES; RENAL DIALYSIS; REPRODUCIBILITY OF RESULTS;

EID: 33644861459     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5000202     Document Type: Letter

References (4)

1. Block GA, Spiegel DM, Ehrlich J et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to dialysis. Kidney Int 2005; 68: 1815-1824.
2. Qunibi WY. Dyslipidemia and progression of cardiovascular calcification (CVC) in patients with end-stage renal disease (ESRD). Kidney Int 2005; 67(Suppl 95): S43-S50.
3. Achenbach S, Ropers D, Pohle K et al. Influence of lipid-lowering therapy on the progression of coronary artery calcification: a prospective evaluation. Circulation 2002; 106: 1077-1082.
4. Chertow GM, Burke SK, Raggi P, for the Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62: 245-252.